Last reviewed · How we verify
NCT07024238: RENOBIOME
Impact of SCFA Supplementation on Gut Microbiome Composition of Kidney Transplant Recipients
NA trial testing SCFA in Metabolic Effects in 41 participants. Enrolling by invitation.
4 September 2025
Quick facts
| Lead sponsor | University Hospital, Martin |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 41 |
| Start date | 4 April 2025 |
| Primary completion | 4 September 2025 |
| Estimated completion | 4 September 2025 |
| Sites | 1 location across Slovakia |
Drugs / interventions tested
- SCFA
- Placebo
Conditions studied
- Metabolic Effects — all drugs for Metabolic Effects →
- Immunosuppressive Agents — all drugs for Immunosuppressive Agents →
- Renal Function — all drugs for Renal Function →
- Adverse Events — all drugs for Adverse Events →
Sponsor
University Hospital, Martin
Who can join
18 and older, any sex, with Metabolic Effects or Immunosuppressive Agents. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of high-dose short-chain fatty acid (SCFA) supplementation on the gut microbiome and host metabolome in stable kidney transplant recipients. Participants will be randomly assigned to receive either 1000 mg of sodium butyrate per day or placebo for a duration of 12 weeks. Comprehensive profiling of the serum and urinary metabolome, along with analysis of the gut microbiome composition and diversity, will be conducted at three time points: baseline, after the intervention period (week 12). The biochemical parameters and the level of tacrolimus will be also examined.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Gut Microbiome-Derived Short-Chain Fatty Acids in Glomerular Protection and Modulation of Chronic Kidney Disease Progression.
Szrejder M, Piwkowska A. · · 2025 · cited 5× · PMID 40944292 · DOI 10.3390/nu17172904 -
Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis.
Zhang CY, Liu S, Sui YX, Yang M. · · 2025 · PMID 41368119 · DOI 10.4254/wjh.v17.i11.113756
Verify or expand the search:
- PubMed search for NCT07024238
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SCFA
Trials testing the same drug.
- NCT06686888 — The Impact of Short-Chain Fatty Acids on Gut Hormone Release After Delivery in the Small and Large Intestine of Healthy · NA · completed
- NCT06082726 — The Systemic Concentration of Short-Chain Fatty Acids After Delivery in the Small and Large Intestine of Healthy Volunte · NA · completed
Other recruiting trials for Metabolic Effects
Currently open trials in the same condition.
- NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
Other University Hospital, Martin trials
Trials by the same sponsor.
- NCT07274462 — DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation) · Phase 4 · active not recruiting
- NCT07338929 — Physical Performance Assessment in Kidney Transplant Evaluation · recruiting
- NCT06929637 — Amino Acid Infusion in Kidney Transplant Recipients · NA · not yet recruiting
- NCT07081126 — Daratumumab for Late Antibody-Mediated Rejection · NA · recruiting
- NCT07055984 — Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07024238 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Martin
- Last refreshed: 17 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07024238.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing